Drug intelligence / Profile preview

Neuro-3

Development stage: Preclinical
Lead developer: Neuro3 Therapeutics
Modality: Small Molecules
Administration: Oral, Sublingual, Buccal

Overview

Neuro-3 is a discovery-stage therapeutic program being developed by Interdict Bio for the treatment of Alzheimer's disease. The program utilizes Interdict Bio's proprietary platform to target specific biological pathways involved in the pathogenesis and progression of Alzheimer's. As of early 2024, the program is in the discovery phase, and Interdict Bio is actively seeking strategic partnerships to advance the candidate through preclinical and clinical development.

Targets

PTC (50S ribosomal peptidyl transferase center)

Beyond the preview

Go deeper on Neuro-3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neuro-3.

Explore the full profile